gpt-dict.com

Curcumin for Anxiety

Verdict: Published with Warning

Across 5 PubMed studies, the evidence for Curcumin in Anxiety grades Tier B — preliminary evidence. Effective, but with safety or population caveats.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.61
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
71%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.48
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.75
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.608
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Clinician guidelines for treatment of psychiatric disorders with nutraceuticals/phytoceuticals: WFSBP & CANMAT Taskforce
PMID: 35311615 2022 系統性回顧
Finding: The WFSBP/CANMAT taskforce found NO nutraceutical/phytoceutical with sufficient evidence for any anxiety-related disorder beyond ashwagandha, galphimia and lavender; curcumin was provisionally recommended (++) ONLY for unipolar depression and was not listed for anxiety.
🟢 High quality Academic Effect size: Curcumin = '++ Provisionally Recommended' for unipolar depression only; not recommended / not listed for anxiety disorders
View on PubMed
Potential therapeutic benefits of curcumin in depression or anxiety induced by chronic diseases: a systematic review of mechanistic and clinical evidence
PMID: 40918536 2025 統合分析 n = 1,123
Finding: Across 15 RCTs (n=1,123) curcumin produced a small but statistically significant reduction in anxiety symptoms (SMD -0.22, 95% CI -0.40 to -0.05, p=0.01) with no heterogeneity in the anxiety subgroup (I2=0%).
Academic Effect size: SMD -0.22 (95% CI -0.40 to -0.05; p=0.01; I2=0%) for anxiety
View on PubMed
Effect of curcumin supplementation on symptoms of anxiety: A systematic review and meta-analysis of randomized controlled trials
PMID: 38857152 2024 統合分析 n = 567
Finding: Pooling 8 RCTs (n=567) gave a very large reduction in anxiety symptoms (SMD -1.56, 95% CI -2.48 to -0.64, p<0.001) but with extreme heterogeneity (I2=95.6%), indicating likely small-study/publication bias and an unreliable effect magnitude.
🟠 Limited quality Academic Effect size: SMD -1.56 (95% CI -2.48 to -0.64; p<0.001; I2=95.6%)
View on PubMed
An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial
PMID: 25776839 2015 RCT (double-blind) n = 30
Finding: In 30 obese adults, curcumin significantly reduced BAI anxiety scores (P=0.03) but had no effect on BDI depression scores (P=0.7); the population was obese individuals, not an anxiety-disorder cohort.
🟠 Limited quality Academic Effect size: BAI reduction P=0.03 (no numeric SMD reported); BDI P=0.7 (null)
View on PubMed
The Effect of Adding Curcumin to Sertraline in the Treatment of Severe Major Depressive Disorder: A Randomized, Double-Blind Clinical Trial
PMID: 37071480 2023 RCT (double-blind) n = 45
Finding: Adding 40 mg/day curcumin to sertraline in 45 severe MDD patients produced no significant between-group difference in anxiety or depression over 8 weeks (P>0.05); anxiety was numerically lower in the curcumin arm but not significant.
Academic Effect size: No significant between-group difference (P>0.05) for anxiety or depression
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4b EU EFSA
Cautious
the Panel established an ADI for curcumin of 3 mg/kg bw/day source↗
L4c UK NHS
Cautious
Avoid turmeric and curcumin in individuals with bile duct obstruction, cholangitis, liver disease, gallstones, or any biliary disease. source↗
L4d TW TFDA / 衛福部
Cautious
薑黃素每人每日攝取量為每公斤體重0~3毫克，每日不超過200毫克為宜 source↗
L4e WHO
Neutral
Rhizoma Curcumae Longae source↗
L5a NIH Office of Dietary Supplements
Cautious
We don't know enough to definitively conclude if turmeric or curcumin is beneficial for any health purposes. source↗
L5b Mayo Clinic
Cautious
Limited data in small studies show turmeric's effectiveness in providing some improvement in anxiety and depression. However, the Food and Drug Administration hasn't approved turmeric in any form for any use, and high-quality human studies are needed to confirm these findings and guide effective and safe use of turmeric as a supplement. source↗
L5c Cleveland Clinic
Neutral
curcumin may also increase levels of serotonin and dopamine, which are chemicals in your brain that regulate mood and other body functions. source↗
L5d Harvard Health
Cautious
Spices with both antioxidant and anti-anxiety properties include turmeric (containing the active ingredient curcumin). source↗
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-anxiety-INT-curcumin-001 繁體中文版 →